{"id":"W4412634163","doi":"10.1177/17588359251357719","title":"Role of immune checkpoint inhibitor combinations in resectable and unresectable, embolization-eligible hepatocellular carcinoma","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Toronto General Hospital; University of Toronto; Dalhousie University; University of Calgary; Spinal Cord Injury BC; University of British Columbia; Princess Margaret Cancer Centre; BC Cancer Agency; Nova Scotia Health Authority; BC Cancer Foundation; Juravinski Cancer Centre","funders":"Eisai Canada; AstraZeneca Canada","keywords":"Medicine; Atezolizumab; Bevacizumab; Lenvatinib; Clinical endpoint; Oncology; Durvalumab; Internal medicine; Hepatocellular carcinoma; Embolization; Perioperative; Sorafenib; Clinical trial; Nivolumab; Surgery; Immunotherapy; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00119219,0.0004656657,0.003203881,0.0009870168,0.00005784242,0.000008824302,0.000297941,0.0009465626,0.000276896],"category_scores_gemma":[0.0004779723,0.0003804672,0.0003020718,0.001520615,0.000403023,0.0001180042,0.0001972201,0.0009710836,0.000007987905],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005086076,"about_ca_system_score_gemma":0.002414222,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002184713,"about_ca_topic_score_gemma":0.000184644,"domain_scores_codex":[0.995883,0.0006974783,0.001746402,0.0005963574,0.0005343232,0.0005424512],"domain_scores_gemma":[0.9975001,0.001308957,0.0004178316,0.0004420105,0.0001197238,0.0002113278],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001257319,0.001199117,0.04081959,0.01435209,0.0001324354,0.0003191337,0.0002250377,4.100048e-7,0.00001350102,0.001992998,0.000005789276,0.9408142],"study_design_scores_gemma":[0.006497068,0.001348972,0.0006093726,0.02310073,0.001088548,0.0001736751,0.0002481462,0.001669725,0.0002252629,0.004557315,0.9600016,0.0004795551],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002701792,0.9879209,0.00005855231,0.0002379431,0.0002084354,0.00204436,0.00001573142,0.00002928079,0.006783044],"genre_scores_gemma":[0.07714983,0.921407,0.0002292523,0.00007742085,0.00007739181,0.0006050986,0.0001823299,0.00004364691,0.0002280655],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9599959,"threshold_uncertainty_score":0.9998647,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04158528642405861,"score_gpt":0.3582130287363358,"score_spread":0.3166277423122772,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}